Does TENIPOSIDE Cause Second primary malignancy? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Second primary malignancy have been filed in association with TENIPOSIDE. This represents 2.2% of all adverse event reports for TENIPOSIDE.
7
Reports of Second primary malignancy with TENIPOSIDE
2.2%
of all TENIPOSIDE reports
5
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From TENIPOSIDE?
Of the 7 reports, 5 (71.4%) resulted in death, 2 (28.6%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TENIPOSIDE. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does TENIPOSIDE Cause?
Ototoxicity (71)
Off label use (61)
Product use in unapproved indication (53)
Leukopenia (25)
Bronchopulmonary aspergillosis (21)
Anaemia (20)
Histiocytosis haematophagic (18)
Left ventricular dysfunction (16)
Pancytopenia (16)
Alopecia (13)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TENIPOSIDE Alternatives Have Lower Second primary malignancy Risk?
TENIPOSIDE vs TENOFOVIR
TENIPOSIDE vs TENOFOVIR ALAFENAMIDE
TENIPOSIDE vs TENOFOVIR DISOPROXIL
TENIPOSIDE vs TEPLIZUMAB-MZWV
TENIPOSIDE vs TEPOTINIB